PRMT5 and neoplasm: With chemical mastery, we can develop a small molecule that selectively binds to PRMT5 only in the presence of MTA killing tumor cells while sparing healthy ones, which may represent a synthetic lethal‐based precision medicine for patients with these cancers [36].